EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Realizing the promise of ‘La Dolce Vita’ via chemical biology: glycan‐motif editing of sLe X for precision cancer therapeutics

Barbara Richichi iD, Robert Sackstein

The FEBS Journal · 2025

DOI: 10.1111/febs.70079 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, 2025. Written by Barbara Richichi and 1 co-authors. Institution: Department of Chemistry 'Ugo Schiff', University of Firenze, Italy. Major MEDLINE topics: Neoplasms, Polysaccharides, Precision Medicine, Oligosaccharides. Cited 4 times so far (Crossref); 82 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, H2020 Marie Skłodowska-Curie Actions, United States National Institutes of Health/National Cancer Institute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The convergence of glycochemistry and glycobiology is enabling the creation of new therapeutic approaches with unprecedented capacity to alter cell and organismic biology using strategies that can uniquely and specifically custom‐modify the expression of key cell surface glycan motifs. We define this evolving field of chemical biology as ‘glycan‐motif editing’, and one of the principal targets of this glycoengineering effort is the sialofucosylated terminal lactosaminyl glycan known as sLe X (CD15s). This tetrasaccharide structure plays pivotal roles in both steady‐state and malignant hematopoiesis, in regulation of the immune response, and in cancer metastasis. Within this biological framework, we discuss the immense potential of glycan‐motif editing in enabling precision therapeutics that will profoundly improve outcomes for patients suffering from a wide variety of disabling and life‐threatening conditions, particularly cancer.

Subjects

MeSH terms (MEDLINE)

NeoplasmsPolysaccharidesPrecision MedicineOligosaccharidesHumansAnimals

Author keywords

E‐selectinE‐selectin ligandfucosyltransferasefucosyltransferase inhibitorglycan‐motif editingglycocalyxglycocalyx editingglycomimeticssLeXtranslational glycobiology

Substances

PolysaccharidesOligosaccharides

Authors and institutions

  • Department of Chemistry 'Ugo Schiff', University of Firenze, Italy.
  • Department of Translational Medicine, and Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.

ORCID profiles: Barbara Richichi

Funding

  • NCI NIH HHS
  • H2020 Marie Skłodowska-Curie Actions
  • United States National Institutes of Health/National Cancer Institute

Cite

APA

Richichi, B., & Sackstein, R. (2025). Realizing the promise of ‘La Dolce Vita’ via chemical biology: glycan‐motif editing of sLe X for precision cancer therapeutics. The FEBS Journal. https://doi.org/10.1111/febs.70079

Vancouver

Richichi B, Sackstein R. Realizing the promise of ‘La Dolce Vita’ via chemical biology: glycan‐motif editing of sLe X for precision cancer therapeutics. The FEBS Journal. 2025. doi:10.1111/febs.70079

BibTeX
@article{Richichi2025,
  author = {Richichi, Barbara and Sackstein, Robert},
  title = {Realizing the promise of ‘La Dolce Vita’ via chemical biology: glycan‐motif editing of sLe X for precision cancer therapeutics},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70079}
}
Start for free →